Cited 6 times in
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜련 | - |
dc.date.accessioned | 2023-04-07T01:27:20Z | - |
dc.date.available | 2023-04-07T01:27:20Z | - |
dc.date.issued | 2022-12 | - |
dc.identifier.issn | 1525-7304 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/193929 | - |
dc.description.abstract | Background: Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor with demonstrated efficacy in locally advanced and metastatic non-small cell lung cancer (NSCLC) in crizotinib-refractory and ALK inhibitor-naive settings. This analysis assessed brigatinib in Asian vs. non-Asian patients from the first-line ALTA-1L trial. Patients and methods: This was a subgroup analysis from the phase III ALTA-1L trial of brigatinib vs. crizotinib in ALK inhibitor-naive ALK+ NSCLC. The primary endpoint was progression-free survival (PFS) as assessed by blinded independent review committee (BIRC). Secondary endpoints included confirmed objective response rate (ORR) and overall survival (OS) in the overall population and BIRC-assessed intracranial ORR and PFS in patients with brain metastases. Results: Of the 275 randomized patients, 108 were Asian. Brigatinib showed consistent superiority in BIRC-assessed PFS vs. crizotinib in Asian (hazard ratio [HR]: 0.35 [95% CI: 0.20-0.59]; log-rank P = .0001; median 24.0 vs. 11.1 months) and non-Asian (HR: 0.56 [95% CI: 0.38-0.84]; log-rank P = .0041; median 24.7 vs. 9.4 months) patients. Results were consistent with investigator-assessed PFS and BIRC-assessed intracranial PFS. Brigatinib was well tolerated. Toxicity profiles and dose modification rates were similar between Asian and non-Asian patients. Conclusion: Efficacy with brigatinib was consistently better than with crizotinib in Asian and non-Asian patients with locally advanced or metastatic ALK inhibitor-naive ALK-+ NSCLC. There were no clinically notable differences in overall safety in Asian vs. non-Asian patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | CLINICAL LUNG CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Asian People | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung* / drug therapy | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung* / ethnology | - |
dc.subject.MESH | Crizotinib / adverse effects | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms* / drug therapy | - |
dc.subject.MESH | Lung Neoplasms* / ethnology | - |
dc.subject.MESH | Lung Neoplasms* / pathology | - |
dc.subject.MESH | Protein Kinase Inhibitors / therapeutic use | - |
dc.title | Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Myung J Ahn | - |
dc.contributor.googleauthor | Hye R Kim | - |
dc.contributor.googleauthor | James C H Yang | - |
dc.contributor.googleauthor | Ji-Yu Han | - |
dc.contributor.googleauthor | Jacky Yu-Chung Li | - |
dc.contributor.googleauthor | Maximilian J Hochmair | - |
dc.contributor.googleauthor | Gee-Chen Chang | - |
dc.contributor.googleauthor | Angelo Delmonte | - |
dc.contributor.googleauthor | Ki H Lee | - |
dc.contributor.googleauthor | Rosario G Campelo | - |
dc.contributor.googleauthor | Cesare Gridelli | - |
dc.contributor.googleauthor | Alexander I Spira | - |
dc.contributor.googleauthor | Raffaele Califano | - |
dc.contributor.googleauthor | Frank Griesinger | - |
dc.contributor.googleauthor | Sharmistha Ghosh | - |
dc.contributor.googleauthor | Enriqueta Felip | - |
dc.contributor.googleauthor | Dong-Wan Kim | - |
dc.contributor.googleauthor | Yuyin Liu | - |
dc.contributor.googleauthor | Pingkuan Zhang | - |
dc.contributor.googleauthor | Sanjay Popat | - |
dc.contributor.googleauthor | D Ross Camidge | - |
dc.identifier.doi | 10.1016/j.cllc.2022.07.008 | - |
dc.contributor.localId | A01166 | - |
dc.relation.journalcode | J03603 | - |
dc.identifier.eissn | 1938-0690 | - |
dc.identifier.pmid | 36038416 | - |
dc.subject.keyword | ALK TKI-naïve | - |
dc.subject.keyword | Anaplastic lymphoma kinase | - |
dc.subject.keyword | Clinical trial | - |
dc.subject.keyword | First line | - |
dc.subject.keyword | Tyrosine kinase inhibitor | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | 김혜련 | - |
dc.citation.volume | 23 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 720 | - |
dc.citation.endPage | 730 | - |
dc.identifier.bibliographicCitation | CLINICAL LUNG CANCER, Vol.23(8) : 720-730, 2022-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.